Analysts Admire Argenx's Vyvgart Launch
Pipeline-In-A-Product Off To Strong Start
Executive Summary
The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.
You may also be interested in...
AstraZeneca’s Ambitious Plans For Alexion
The UK major’s CEO, Pascal Soriot, said the setting-up of a new R&D hub in Cambridge, MA, which will also serve as the new corporate headquarters for Alexion, is "a milestone moment" for the rare diseases unit.
Argenx, Calliditas Hit The Ground Running After FDA Approvals
Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.
Almirall Views Vitiligo As Next Dermatology Opportunity
As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.